53

Samrat Pharmachem LtdBOM 530125 Stock Report

Last reporting period 31 Mar, 2024

Updated 12 Nov, 2024

Last price

Market cap $B

0.003

Micro

Exchange

XBOM - Bombay Stock Exchange

530125.BO Stock Analysis

53

Avoid

Based on Eyestock quantitative analysis, 530125.BO`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

46/100

Low score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-87.4 %

Greatly overvalued

Market cap $B

0.003

Dividend yield

0.16 %

Shares outstanding

3.09 B

Samrat Pharmachem Ltd. engages in the manufacturing manufacturing and selling chemicals. The company is headquartered in Mumbai, Maharashtra. The firm is a supplier of iodine derivatives to the Indian and foreign market. The Company’s products include 3-5-Di Iodosalicylic Acid, Ammonium Iodide, Calcium Iodide, Clioquinol, Copper Iodide, Ethyl Iodide, Ethylenediamine Dihydroiodide, Hydroiodic Acid 57%, Iodic Acid, Iodine, Iodine Monochloride, Iodoquinol, Lithium Iodide, Methyl Iodide, N-Iodo Succcinimide, Periodic Acid, Potassium Iodate, Potassium Iodide, Potassium Metaper Iodate, Povidone Iodine, Selenium Dioxide, Sodium Iodate, Sodium Iodide, Sodium Metaper Iodate, Sodium Selenite, Tetra Butyl Ammonium Iodide, and Tri Methyl Sulphoxonium Iodide. The company serves various industries, such as agrochemical, animal feed, chemicals, food, pharmaceutical, printing, and textile. The firm exports its products to various countries, including United States, Europe, Africa, Asia, and Middle East.

View Section: Eyestock Rating